The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Open accessThe DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Abstract
Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)](https://figures.cochat.ai/paper-figures/47a9baa04bb54a408b711fbf0d4e6807/the-evolution-of-insulin-and-how-it-informs-therapy-and-treatment-choices-figure-2.jpg)
















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Towards a goal of reducing the need for multiple daily injections, the first long-acting insulin was developed in the 1930s by H. C. Hagedorn. It was a suspension protamine zinc insulin that was based on the discovery that insulin action could be prolonged by adding protamine obtained from river trout semen106. The action of protamine zinc insulin lasted 24–36 h.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These insulins reduce postprandial hyperglycemia but have otherwise not been shown to reduce HbA 1c or hypoglycemia to a greater extent than rapid-acting analogs (3).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“After injection and dilution of the phenolic preservative in the SC space, the dihexamers selfassociate, forming multihexamer complexes (60).”
BackgroundThe Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429 · cited 1×
“The fatty acyl side chain also enables binding to serum albumin, a long-lived plasma protein, thus slowing the disposition of detemir to peripheral tissues and clearance from the body (53).”
BackgroundBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 1×
“A 3-fold concentrated version of insulin glargine was developed to prolong the duration of action when the results of 2 preliminary studies showed less diurnal variation in glucose-lowering activity with U-300 compared to the same dose of U-100 glargine (46).”
ResultGlucose Sensing in Pancreatic β-Cells
Schuit, F. C., Huypens, P., Heimberg, H., & Pipeleers, D. G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.1 · Cited by 405
Human Insulin from Recombinant DNA Technology
Johnson, I. S. (1983) · Science · doi:10.1126/science.6337396 · Cited by 401
Zinc–Ligand Interactions Modulate Assembly and Stability of the Insulin Hexamer – A Review
Dunn, M. F. (2005) · BioMetals · doi:10.1007/s10534-005-3685-y · Cited by 335 · cited 1×
“(3) insulin hexamers dissociate into dimers then monomers in the SC space; (4) the size of the monomers permits absorption across the microvascular endothelium into the”
BackgroundKurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U. D., Ribel, U., & Markussen, J. (1995) · Biochemical Journal · doi:10.1042/bj3120725 · Cited by 334 · cited 1×
“The fact that most of the circulating insulin detemir or insulin degludec is bound to albumin reduces the amount of free drug available for engagement with the insulin receptor, whereas insulin glargine is all available as free drug to bind the insulin receptors (65).”
BackgroundAmino-Acid Sequence of Human Insulin
NICOL, D. S. H. W., & SMITH, L. F. (1960) · Nature · doi:10.1038/187483a0 · Cited by 334 · cited 3×
“B: (1) Regular insulin is formulated as hexamers in the presence of zinc; (2) insulin is injected into the SC space;”
BackgroundMethodInsulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Immunogenicity and Allergenic Potential of Animal and Human Insulins
Schernthaner, G. (1993) · Diabetes Care · doi:10.2337/diacare.16.3.155 · Cited by 247 · cited 2×
“A common problem with animal-source insulins, however, was the formation of anti-insulin antibodies, which led to lipoatrophy and insulin resistance in a significant percentage of patients (6, 7).”
BackgroundRitzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12485 · Cited by 236 · cited 1×
“In studies in type 2 diabetes, subjects needed an average of 12% more U-300 than U-100 insulin glargine for the same glycemic effect (50).”
BackgroundMeneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221 · cited 1×
“5% more U-300 than U-100 insulin glargine for the same glycemic control (49).”
BackgroundPorcellati, F., Rossetti, P., Busciantella, N. R., Marzotti, S., Lucidi, P., Luzio, S., Owens, D. R., Bolli, G. B., & Fanelli, C. G. (2007) · Diabetes Care · doi:10.2337/dc07-0002 · Cited by 219
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0514-8 · Cited by 182 · cited 1×
“L-arginine acts as a stabilizing agent, while niacinamide accelerates absorption at the site of injection (31).”
BackgroundBruttomesso, D., Pianta, A., Mari, A., Valerio, A., Marescotti, M. C., Avogaro, A., Tiengo, A., & Del Prato, S. (1999) · Diabetes · doi:10.2337/diabetes.48.1.99 · Cited by 166
Swinnen, S. G., Dain, M.-P., Aronson, R., Davies, M., Gerstein, H. C., Pfeiffer, A. F., Snoek, F. J., DeVries, J. H., Hoekstra, J. B., & Holleman, F. (2010) · Diabetes Care · doi:10.2337/dc09-2294 · Cited by 159
Heise, T., Hövelmann, U., Nosek, L., Hermanski, L., Bøttcher, S. G., & Haahr, H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1058779 · Cited by 152
Galloway, J. A., Hooper, S. A., Spradlin, C. T., Howey, D. C., Frank, B. H., Bowsher, R. R., & Anderson, J. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.5.666 · Cited by 139 · cited 4×
“(3) insulin hexamers dissociate into dimers then monomers in the SC space; (4) the size of the monomers permits absorption across the microvascular endothelium into the”
BackgroundMethodInfluentialEvolution of Diabetes Technology
Dovč, K., & Battelino, T. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.009 · Cited by 132 · cited 1×
“To facilitate this process, “connected” pens are being developed that link to smartphonebased diabetes management apps (100).”
Backgroundde la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125 · cited 2×
“U-500 insulin retains the bolus properties of regular insulin but also has a longer duration of action (84).”
BackgroundEvolution of Diabetes Insulin Delivery Devices
Selam, J.-L. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400302 · Cited by 116 · cited 1×
“Insulin pens offer benefits to patients, including more accurate dosing, ease of use, more social acceptability, and less time to prepare and administer injections (99).”
BackgroundHeise, T., Nosek, L., Dellweg, S., Zijlstra, E., Præstmark, K. A., Kildegaard, J., Nielsen, G., & Sparre, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12304 · Cited by 114
Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin
Heise, T., Weyer, C., Serwas, A., Heinrichs, S., Osinga, J., Roach, P., Woodworth, J., Gudat, U., & Heinemann, L. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.800 · Cited by 110
Ashwell, S. G., Gebbie, J., & Home, P. D. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01913.x · Cited by 109 · cited 1×
“Glargine is given once daily in most patients, but in some instances it may need to be given twice daily (44).”
BackgroundLinnebjerg, H., Lam, E. C. Q., Seger, M. E., Coutant, D. E., Chua, L., Chong, C. L., Ferreira, M. M., Soon, D., & Zhang, X. (2015) · Diabetes Care · doi:10.2337/dc14-2623 · Cited by 101
Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes
SA, B., BP, K., D, R., JW, L., BA, B., YC, K., LM, L., CJ, L., JE, P., RP, W., et al. (2020) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.17.10.13 · Cited by 95
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin
Heinemann, L., Baughman, R., Boss, A., & Hompesch, M. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816658055 · Cited by 84 · cited 1×
“Unlike other rapid-acting and ultrarapid insulins, which are analogs of human insulin, Afrezza is a recombinant human regular insulin that has been formulated as a dry powder to be inhaled into the lungs via its dedicated device (33, 34).”
BackgroundLucidi, P., Porcellati, F., Andreoli, A. M., Carriero, I., Candeloro, P., Cioli, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc15-0801 · Cited by 81 · cited 1×
“If this resuspension process is not followed, it can add significantly to the day-today variability, which is substantial even in a controlled study (42).”
BackgroundThe past, present, and future of basal insulins
Pettus, J., Santos Cavaiola, T., Tamborlane, W. V., & Edelman, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 80
Pampanelli, S., Torlone, E., Ialli, C., Sindaco, P. D., Ciofetta, M., Lepore, M., Bartocci, L., Brunetti, P., & Bolli, G. B. (1995) · Diabetes Care · doi:10.2337/diacare.18.11.1452 · Cited by 79 · cited 1×
“3C, where the PK profiles of endogenously secreted insulin (in healthy volunteers) and SC-administered human regular insulin (in persons with type 1 diabetes) following a meal are shown (24).”
BackgroundHirsch, I. B., Bode, B., Courreges, J.-P., Dykiel, P., Franek, E., Hermansen, K., King, A., Mersebach, H., & Davies, M. (2012) · Diabetes Care · doi:10.2337/dc11-2503 · Cited by 76
Self-citationHeise, T., Nosek, L., Roepstorff, C., Chenji, S., Klein, O., & Haahr, H. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0070-2 · Cited by 75 · cited 1×
“14, as well as Ryzodeg single dose given to subjects who had achieved steady state on insulin degludec (75, 76).”
BackgroundInsulin degludec: overview of a novel ultra long‐acting basal insulin
Gough, S. C. L., Harris, S., Woo, V., & Davies, M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12052 · Cited by 74 · cited 2×
“The time-action profile of insulin degludec at steady state with once-daily dosing is characterized by a near-constant plasma level with minimal peak to trough, reducing day-to-day variability (61).”
BackgroundHeise, T., Stender-Petersen, K., Hövelmann, U., Jacobsen, J. B., Nosek, L., Zijlstra, E., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0473-5 · Cited by 73
de la Peña, A., Seger, M., Soon, D., Scott, A. J., Reddy, S. R., Dobbins, M. A., Brown‐Augsburger, P., & Linnebjerg, H. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.221 · Cited by 67
Jet Injection of Insulin During Self-Monitoring of Blood Glucose
Danowski, T. S., & Sunder, J. H. (1978) · Diabetes Care · doi:10.2337/diacare.1.1.27 · Cited by 62 · cited 1×
“There was a recognized need for longer-acting insulin to provide better betweenmeal coverage, as well as a faster-acting/fasterdissipating insulin for mealtime use (the concept of basal/bolus therapy) (23).”
BackgroundHood, R. C., Arakaki, R. F., Wysham, C., Li, Y. G., Settles, J. A., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15612.or · Cited by 61 · cited 1×
“This attribute facilitates the use of U-500R as insulin monotherapy, which was tested and shown to significantly improve HbA1c in patients with type 2 diabetes inadequately controlled on high doses of U-100R therapy (> 200 units/day) (89).”
MethodA Comparison of Accuracy and Estimated Cost of Methods for Home Blood Glucose Monitoring
Shapiro, B., Savage, P. J., Lomatch, D. L., Gniadek, T. J., Forbes, R., Mitchell, R. J., Hein, K., Starr, R., Nutter, M., & Scherdt, B. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.396 · Cited by 61 · cited 1×
“This situation was complicated by the lack of home blood glucose monitoring technology, an advance that did not come until the late 1970s (21, 22).”
BackgroundBanting's, Best's, and Collip's accounts of the discovery of insulin.
Bliss, M. (1982) · PubMed · Cited by 57
Human insulin (Novo): chemistry and characteristics.
Markussen, J., Damgaard, U., Pingel, M., Snel, L. I. P., Sørensen, A. R., & Sørensen, E. (1983) · PubMed · Cited by 55
Establishment of Time-Action Profiles for Regular and NPH Insulin Using Pharmacodynamic Modeling
Woodworth, J. R., Howey, D. C., & Bowsher, R. R. (1994) · Diabetes Care · doi:10.2337/diacare.17.1.64 · Cited by 55 · cited 1×
“8, we show how the PK and PD of NPH insulin and human regular insulin compare (39).”
BackgroundHallas-Møller, K., Jersild, M., Petersen, K., & Schlichtkrull, J. (1952) · JAMA · doi:10.1001/jama.1952.03680170021006 · Cited by 53 · cited 1×
“Lente insulins include semilente, lente, and ultralente, with the extent of amorphous to crystalline insulin determining the duration of activity (37, 38).”
BackgroundHagedorn, H. C. (1984) · JAMA · doi:10.1001/jama.251.3.389 · Cited by 51
Lucidi, P., Porcellati, F., Rossetti, P., Candeloro, P., Cioli, P., Marzotti, S., Andreoli, A. M., Fede, R., Bolli, G. B., & Fanelli, C. G. (2011) · Diabetes Care · doi:10.2337/dc10-1911 · Cited by 51 · cited 1×
“Those with type 2 diabetes, especially with a higher body mass index, may also need higher doses of insulin detemir compared to insulin glargine or NPH insulin (55, 56).”
BackgroundCheng, A. Y. Y., Patel, D. K., Reid, T. S., & Wyne, K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00925-6 · Cited by 51 · cited 2×
“The higher concentration of glargine delivered in the same volume further slows the dissolution of the glargine precipitate in the SC space, leading to a better basal insulin (48).”
BackgroundThe trials and tribulations of producing the first genetically engineered drug
Johnson, I. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1179 · Cited by 45 · cited 1×
“The discovery of the insulin gene and commercialization of recombinant DNA technology enabled the development and large-scale manufacturing of biosynthetic human insulin (14, 15).”
BackgroundThe pharmacokinetic basis of insulin therapy in diabetes mellitus
Bolli, G. B. (1989) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(89)90073-9 · Cited by 35 · cited 1×
“Under the controlled conditions of the euglycemic clamp, the PD profile of the insulin being tested will mimic the PK profile (18, 19).”
MethodTreatment of insulin lipoatrophy with monocomponent insulin
Teuscher, A. U. (1974) · Diabetologia · doi:10.1007/bf00423037 · Cited by 35 · cited 1×
“A common problem with animal-source insulins, however, was the formation of anti-insulin antibodies, which led to lipoatrophy and insulin resistance in a significant percentage of patients (6, 7).”
BackgroundWu, T., Betty, B., Downie, M. R., Khanolkar, M., Kilov, G., Orr‐Walker, B., Senator, G. B., & Fulcher, G. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0116-0 · Cited by 34 · cited 1×
“748 Endocrine Reviews, October 2020, 41(5):733–755 Hirsch et al The Evolution of Insulin and How it Informs twice, or thrice daily (77, 78).”
Eby, E. L., Wang, P., Curtis, B. H., Xie, J., Haldane, D. C., Idris, I., Peters, A. L., Hood, R. C., & Jackson, J. A. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.772059 · Cited by 31
Sonnenberg, G. E., Chantelau, E. A., Sundermann, S., Hauff, C., & Berger, M. (1982) · Diabetes · doi:10.2337/diab.31.7.600 · Cited by 31
Szekeres, A. V., Worcester, B., Ascher, M. S., Tuxen, D., Heyendal, R., Walsh, K. M., & Charles, M. A. (1983) · Diabetes Care · doi:10.2337/diacare.6.2.193 · Cited by 30
Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?
Watson, L., Wilson, B. P., Alsop, J., & Kumar, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01413.x · Cited by 29 · cited 1×
“Concentrated insulins have been developed for a variety of purposes (79).”
BackgroundU-500 Insulin in the Treatment of Antibody-Mediated Insulin Resistance
Nathan, D. M., AXELROD, L., Flier, J. S., & Carr, D. B. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-5-653 · Cited by 26 · cited 1×
“The first concentrated insulin developed was U-500 (5x concentrated animal-sourced insulin), which was needed to overcome insulin resistance associated with high concentrations of antiinsulin antibodies from animal-sourced insulins (83).”
BackgroundKlatman, E. L., McKee, M., & Ogle, G. D. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107859 · Cited by 26 · cited 2×
“Although a variety of insulins are available that allow therapy to be tailored to individual patients, many patients are experiencing issues related to accessing and affording their therapy (97, 98).”
BackgroundElizarova, S. V., Galstyan, G. R., & Wolffenbuttel, B. H. R. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12096 · Cited by 23 · cited 1×
“748 Endocrine Reviews, October 2020, 41(5):733–755 Hirsch et al The Evolution of Insulin and How it Informs twice, or thrice daily (77, 78).”
BackgroundHeise, T., Nosek, L., Klein, O., Coester, H. V., Svendsen, A. L., & Haahr, H. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12463 · Cited by 23 · cited 1×
“14, as well as Ryzodeg single dose given to subjects who had achieved steady state on insulin degludec (75, 76).”
BackgroundMaternal Adipose Tissue Expansion, A Missing Link in the Prediction of Birth Weight Centile
Jarvie, E. M., Stewart, F. M., Ramsay, J. E., Brown, E. A., Meyer, B. J., Olivecrona, G., Griffin, B. A., & Freeman, D. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz248 · Cited by 22
Human Monocomponent Insulin: Chemistry and Characteristics
Markussen, J., Damgaard, U., Jørgensen, K. H., Sørensen, E., & Thim, L. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb08555.x · Cited by 19
Tham, L. S., Schneck, K. B., Ertekin, A., & Reviriego, J. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.899 · Cited by 19 · cited 1×
“Under the controlled conditions of the euglycemic clamp, the PD profile of the insulin being tested will mimic the PK profile (18, 19).”
MethodBeals, J. M., DeFelippis, M. R., Paavola, C. D., Allen, D. P., Garg, A. K., & Baldwin, D. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_18 · Cited by 19
Self-citationUnderstanding concentrated insulins: a systematic review of randomized controlled trials
Ovalle, F., Segal, A. R., Anderson, J. E., Cohen, M. R., Morwick, T. M., & Jackson, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1409426 · Cited by 16 · cited 1×
“While total insulin exposure (AUCinsulin and Gtot) was not statistically different between U-500R and U-100R, supporting unit dose equivalency (equipotency) (84, 90, 91), they are not bioequivalent and have different time-action profiles (Fig.”
BackgroundOwens, D. R., Jones, M., Birtwell, A. J., Burge, C. T. R., Jones, I. R., Heyburn, P. J., Hayes, T. M., & Hedïng, L. G. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2007-1014932 · Cited by 15 · cited 10×
“742 Endocrine Reviews, October 2020, 41(5):733–755 Hirsch et al The Evolution of Insulin and How it Informs of asparagine at A21 with glycine imparted enhanced chemical stability in a low pH solution (formulated at pH 4).”
BackgroundInfluentialLente Insulin in the Treatment of Diabetes
Slayton, R. E., Burrows, R. E., & Marble, A. (1955) · New England Journal of Medicine · doi:10.1056/nejm195510272531704 · Cited by 13 · cited 1×
“Lente insulins include semilente, lente, and ultralente, with the extent of amorphous to crystalline insulin determining the duration of activity (37, 38).”
BackgroundTransition of Patients to and from Insulin Degludec: A Clinical Challenge
Hirsch, I. B., & Draznin, B. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz280 · Cited by 11 · cited 2×
“This transition is particularly complex when switching from degludec to insulin pump therapy (64).”
BackgroundSelf-citationEby, E. L., Brunt, K. V., Brusko, C., Curtis, B. H., & Lage, M. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.004 · Cited by 8
Kühnau, J., Rüdiger, H. W., & Goetz, K. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1210325 · Cited by 7
Morris, N. (1940) · PubMed Central · Cited by 7
Santeusanio, F., Massi‐Benedetti, M., Clementi, A., Calabrese, G., Bueti, A., Picchio, E., & Brunetti, P. (1981) · PubMed · Cited by 4
Clinical Challenges With Concentrated Insulins: Setting the Record Straight
Brusko, C., Taylor, A. D., Jackson, J. A., & Bunck, M. C. M. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0008 · Cited by 4 · cited 1×
“While total insulin exposure (AUCinsulin and Gtot) was not statistically different between U-500R and U-100R, supporting unit dose equivalency (equipotency) (84, 90, 91), they are not bioequivalent and have different time-action profiles (Fig.”
BackgroundMimouni, M., Galatzer, A., Madanes, L., Lew, E., Doron, M., & Laron, Z. (1978) · PubMed · Cited by 2
Cited by
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (“regular”) human insulin, resulting in reduced early pos…”
InfluentialSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationRole of Insulin in Health and Disease: An Update
Rahman, M. S., Hossain, K. S., Das, S., Kundu, S., Adegoke, E. O., Rahman, M. A., Hannan, M. A., Uddin, M. J., & Pang, M.-G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126403 · Cited by 472
“Exogenous insulins are now available in the form of rapidacting, short-acting, intermediate-acting, and long-acting [16].”
BackgroundHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Self-citation100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270
Metadata
- Authors
- Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E.
- Affiliations
- University of Washington (US)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California
- Charlotte Area Health Education Center, Charlotte, North Carolina
- Corresponding author
- Hirsch, Irl B
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-05-12
- Volume
- 41
- Issue
- 5
- Pages
- 733-755
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7366348
- OpenAlex
- W3024580742
- Cited by
- 237
- References
- 82
- Citations by year
- 2026: 25 · 2025: 50 · 2024: 37 · 2023: 37 · 2022: 45 · 2021: 38 · 2020: 4
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- insulin, insulin formulations, insulin analogues, rapid-acting insulin, long-acting insulin, short-acting insulin, intermediate-acting insulin, insulin mixtures, insulin levels, pharmacokinetics, pharmacodynamics, endogenous insulin, diabetes treatment, insulin replacement therapy
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.